EP1575506A4 - Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern - Google Patents

Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern

Info

Publication number
EP1575506A4
EP1575506A4 EP03771821A EP03771821A EP1575506A4 EP 1575506 A4 EP1575506 A4 EP 1575506A4 EP 03771821 A EP03771821 A EP 03771821A EP 03771821 A EP03771821 A EP 03771821A EP 1575506 A4 EP1575506 A4 EP 1575506A4
Authority
EP
European Patent Office
Prior art keywords
tgf
improvement
methods
lung function
beta inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03771821A
Other languages
English (en)
French (fr)
Other versions
EP1575506A2 (de
Inventor
Zhihe Li
David Y Liu
Jing Ying Ma
Andrew Protter
George F Schreiner
Thomas-Toan Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of EP1575506A2 publication Critical patent/EP1575506A2/de
Publication of EP1575506A4 publication Critical patent/EP1575506A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP03771821A 2002-07-25 2003-07-23 Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern Withdrawn EP1575506A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39936902P 2002-07-25 2002-07-25
US399369P 2002-07-25
PCT/US2003/023240 WO2004010929A2 (en) 2002-07-25 2003-07-23 METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS

Publications (2)

Publication Number Publication Date
EP1575506A2 EP1575506A2 (de) 2005-09-21
EP1575506A4 true EP1575506A4 (de) 2008-04-23

Family

ID=31188573

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03771821A Withdrawn EP1575506A4 (de) 2002-07-25 2003-07-23 Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern

Country Status (4)

Country Link
EP (1) EP1575506A4 (de)
AU (1) AU2003256783A1 (de)
CA (1) CA2494367A1 (de)
WO (1) WO2004010929A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572208A4 (de) * 2002-11-22 2007-08-29 Scios Inc Verfahren, um einer pathologischen veränderungder beta-adrenergen signalübertragung entgegenzuwirken
ATE398125T1 (de) 2003-03-12 2008-07-15 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
WO2006135993A1 (en) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
US8597646B2 (en) * 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2010002998A1 (en) 2008-07-03 2010-01-07 Gilead Sciences, Inc. 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
SG186855A1 (en) 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
AU2012224979B2 (en) 2011-03-09 2017-01-19 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (de) 2011-10-26 2015-05-15 Seattle Childrens Res Inst
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN108727282B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种含苯磺酰氨基的抗炎化合物及其合成方法
CN109053597B (zh) * 2018-06-14 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种炎症抑制化合物及其制备方法
CN108912061B (zh) * 2018-06-14 2021-03-19 温州医科大学 一种喹唑啉类炎症抑制化合物的合成方法
CN108727283B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种苯磺酰氨类抗炎化合物的合成方法
CN108912059B (zh) * 2018-06-14 2021-03-02 温州医科大学附属第一医院 一种含氮杂环炎症抑制化合物的合成方法
CN108912060B (zh) * 2018-06-14 2021-03-19 温州医科大学 一种喹唑啉类抗炎化合物及其合成方法
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
CN112568188B (zh) * 2021-02-24 2021-05-25 澎立生物医药技术（上海）有限公司 一种制作Brown Norway大鼠肺纤维化模型的方法
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439895A (en) * 1992-07-15 1995-08-08 Ono Pharmaceutical Co., Ltd. 4-aminoquinazoline derivatives
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
US6277989B1 (en) * 1998-08-28 2001-08-21 Scios, Inc. Quinazoline derivatives as medicaments
WO2001062756A1 (en) * 2000-02-21 2001-08-30 Smithkline Beecham P.L.C. Pyridinylimidazoles
WO2002022602A2 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002062794A2 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Compounds
US20040038856A1 (en) * 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366189A (en) * 1979-12-21 1982-12-28 Ciba-Geigy Corporation 4-Heterocyclyl-4'-vinylstilbenes
EP1572208A4 (de) * 2002-11-22 2007-08-29 Scios Inc Verfahren, um einer pathologischen veränderungder beta-adrenergen signalübertragung entgegenzuwirken

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439895A (en) * 1992-07-15 1995-08-08 Ono Pharmaceutical Co., Ltd. 4-aminoquinazoline derivatives
US6277989B1 (en) * 1998-08-28 2001-08-21 Scios, Inc. Quinazoline derivatives as medicaments
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
WO2001062756A1 (en) * 2000-02-21 2001-08-30 Smithkline Beecham P.L.C. Pyridinylimidazoles
WO2002022602A2 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002062794A2 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Compounds
US20040038856A1 (en) * 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE BOER WILLEM I ET AL: "Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 158, no. 6, December 1998 (1998-12-01), pages 1951 - 1957, XP002343270, ISSN: 1073-449X *

Also Published As

Publication number Publication date
AU2003256783A1 (en) 2004-02-16
CA2494367A1 (en) 2004-02-05
WO2004010929A2 (en) 2004-02-05
EP1575506A2 (de) 2005-09-21
WO2004010929A3 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
EP1575506A4 (de) Verfahren zur verbesserung der lungenfunktion mit tgf-beta hemmern
EG25482A (en) Inhibitors
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
TWI369354B (en) Cytokine inhibitors
HK1091210A1 (en) Cytokine inhibitors
GB0325192D0 (en) Method of use
AU2003202263A1 (en) Roh-kinase inhibitors
EP1667982A4 (de) Isochinolinon-caliumkanalinhibitoren
EP1667683A4 (de) Chinolin-kaliumkanal-hemmer
EP1667978A4 (de) Isochinolinon-kaliumkanalinhibitoren
EP1569633A4 (de) Ca-ix-spezifische hemmer
EP1532133A4 (de) Nf-:b-inhibitoren
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1667977A4 (de) Isochinolinon-kaliumkanalinhibitoren
ZA200707086B (en) Cytokine inhibitors
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
EP1667973A4 (de) Chinolin-kaliumkanalinhibitoren
AU2003299901A8 (en) Thrombin inhibitors
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
GB0311195D0 (en) Glyoxalase inhibitors
AU2003213107A8 (en) Methods for analysis of molecular events
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003299792A8 (en) Methods for the identification of inhibitors of pyrroline-5-carboxylate reductase as antibiotics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 239/00 19850101ALI20051208BHEP

Ipc: A61K 31/435 19850101ALI20051208BHEP

Ipc: A61K 31/53 19850101AFI20051208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080328

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/06 20060101ALI20080320BHEP

Ipc: A61P 11/00 20060101ALI20080320BHEP

Ipc: C07D 239/00 20060101ALI20080320BHEP

Ipc: A61K 31/435 20060101ALI20080320BHEP

Ipc: A61K 31/53 20060101ALI20080320BHEP

Ipc: A61K 31/4985 20060101ALI20080320BHEP

Ipc: A61K 31/498 20060101ALI20080320BHEP

Ipc: A61K 31/505 20060101ALI20080320BHEP

Ipc: A61K 31/00 20060101AFI20080320BHEP

17Q First examination report despatched

Effective date: 20090402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091013